Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner

Published:2018-02-05 Issue:17 Volume:37 Page:2237-2250
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Rauf Femina,Festa Fernanda,Park Jin G.,Magee Mitchell,Eaton Seron,Rinaldi Capria,Betanzos Carlos Morales,Gonzalez-Malerva Laura,LaBaer Joshua

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-017-0079-x.pdf

Reference31 articles.

1. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.

2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

3. Smith MR. Ibrutinib in B lymphoid malignancies. Exp Opin Pharmacother. 2015;16:1879–87.

4. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175–84.

5. Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015;75:1675–81.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of ibrutinib's effects on the morphology, proliferation, phenotype, viability, and anti-inflammatory potential of adipose-derived mesenchymal stromal cells;Scientific Reports;2024-08-28

2. Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growth;Biochemical Pharmacology;2023-09

3. Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer;Biology;2023-07-04

4. Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines;Investigational New Drugs;2023-03-13

5. Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines;2023-02-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3